Stockholm, 8 May 2026 – The healthtech company FagerCare today announces a significant European expansion. From 1 June, the service is available in 31 countries, making FagerCare one of the most accessible providers of medical weight loss treatment in Europe.

FagerCare offers medically supervised weight loss using the latest GLP-1 medications – including Mounjaro and Wegovy – entirely digitally and at some of the lowest prices on the market. The process is straightforward: a digital consultation with a licensed physician, an individual assessment and, where treatment is appropriate, a prescription. No long waiting lists. No expensive clinic visits. No lock-in contracts.

One of FagerCare's key advantages is the freedom to collect medication from any pharmacy or online pharmacy, giving patients the ability to always choose the most affordable option.

– We are proud to now offer more Europeans access to modern, affordable weight loss treatment. Whether you are in Stockholm, Madrid or Warsaw, access to qualified medical care should be equally simple, says Marcus Everflod, partner and head of FagerCare's digital infrastructure.

FagerCare is also continuing to develop its range of services, including longevity-focused offerings and the opening of an exclusive clinic later this year, aimed at patients with chronic conditions.

About FagerCare
FagerCare is a digital healthcare service specialising in medical weight loss. The company was founded by Dr Frida Fagerdahl and Specialist Tony Fagerdahl and from June 2025 offers its services in 31 European countries. The digital platform is developed and operated in partnership with Searchminds.
For more information: www.fagercare.com

Press contact:
Marcus Everflod
[email protected]